Wellington Management Group LLP Inhibrx, Inc. Transaction History

Wellington Management Group LLP

$548 Billion
Q2 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$32.76 - $39.56 $4.26 Million - $5.14 Million	130,044 New	130,044 $4.55 Million
Q4 2023 Feb 12, 2024	BUY	$14.5 - $38.0 $2.11 Million - $5.53 Million	145,398 New	145,398 $5.53 Million
Q3 2023 Nov 14, 2023	BUY	$15.75 - $26.31 $540,382 - $902,696	34,310 Added 24.4%	174,899 $3.21 Million
Q2 2023 Aug 14, 2023	BUY	$16.96 - $27.82 $639,256 - $1.05 Million	37,692 Added 36.63%	140,589 $3.65 Million
Q1 2023 May 12, 2023	SELL	$18.45 - $27.14 $14.7 Million - $21.7 Million	-798,085 Reduced 88.58%	102,897 $1.94 Million
Q4 2022 Feb 13, 2023	SELL	$20.18 - $33.33 $2.26 Million - $3.72 Million	-111,758 Reduced 11.04%	900,982 $22.2 Million
Q3 2022 Nov 14, 2022	BUY	$11.58 - $24.73 $6.84 Million - $14.6 Million	590,536 Added 139.87%	1,012,740 $18.2 Million
Q2 2022 Aug 15, 2022	BUY	$8.52 - $25.26 $2.59 Million - $7.67 Million	303,698 Added 256.27%	422,204 $4.79 Million
Q1 2022 May 16, 2022	SELL	$19.89 - $43.18 $27.5 Million - $59.6 Million	-1,381,018 Reduced 92.1%	118,506 $2.64 Million
Q4 2021 Feb 11, 2022	SELL	$26.75 - $46.02 $7.66 Million - $13.2 Million	-286,508 Reduced 16.04%	1,499,524 $65.5 Million
Q3 2021 Nov 15, 2021	SELL	$25.18 - $37.81 $9.07 Million - $13.6 Million	-360,163 Reduced 16.78%	1,786,032 $59.5 Million
Q2 2021 Aug 16, 2021	BUY	$14.69 - $27.52 $2.49 Million - $4.67 Million	169,714 Added 8.59%	2,146,195 $59.1 Million
Q1 2021 May 17, 2021	BUY	$16.27 - $41.26 $32.2 Million - $81.5 Million	1,976,481 New	1,976,481 $39.7 Million
Q4 2020 Feb 12, 2021	SELL	$15.96 - $50.0 $322,423 - $1.01 Million	-20,202 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$16.77 - $20.65 $338,787 - $417,171	20,202 New	20,202 $364,000

Others Institutions Holding INBX

# of Institutions

Shares Held

25.3K

Call Options Held

Put Options Held

View Full List

About Inhibrx, Inc.

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $617M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

More about INBX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wellington Management Group LLP, based on Form 13F filings with the SEC.

News

Stay updated on Wellington Management Group LLP with notifications on news.

Account